Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 4, 2014, Pages 1299-1313

  Matsuda, Yasunobu ^a   Wakai, Toshifumi ^b   Kubota, Masayuki ^b   Osawa, Mami ^b   Hirose, Yuki ^b   Sakata, Jun ^b   Kobayashi, Takashi ^b   Fujimaki, Shun ^a   Takamura, Masaaki ^b   Yamagiwa, Satoshi ^b   Aoyagi, Yutaka ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Hepatocellular carcinoma; Sorafenib; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE; PROTEIN KINASE B; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; VALPROIC ACID;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LIVER NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT FAILURE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84899578829     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Llovet JM, Burroughs A and Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
3. Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J and Xiang YB. Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev 2012; 13: 743-752.
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
5. Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y and Hatakeyama K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg 2011; 15: 1450-1458.
6. Matsuda Y, Ichida T and Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011; 44: 117-124.
7. Llovet JM and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
8. Villanueva A and Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426.
9. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
10. Matsuda Y and Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011; 44: 183-189.
11. El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem 2014; 72: 170-205.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
13. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
14. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E and Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-222.
15. Cui W, Yu CH and Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 8213-8221.
16. Lawler OA, Miggin SM and Kinsella BT. The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. Br J Pharmacol 2001; 132: 1639-1649.
17. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME and Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
18. Rose A, Grandoch M, vom Dorp F, Rubben H, Rosenkranz A, Fischer JW and Weber AA. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 2010; 160: 1690-1698.
19. Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, Yamagiwa S, Yano M, Ohkoshi S and Aoyagi Y. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett 2012; 319: 98-108.
20. Border WA and Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
21. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C and Peck-Radosavljevic M. Sorafe-nib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.
22. Schutte K, Zimmermann L, Bornschein J, Csepregi A, Ruhl R, Ricke J and Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion 2011; 83: 275-282.
23. Chen YL, Lv J, Ye XL, Sun MY, Xu Q, Liu CH, Min LH, Li HP, Liu P and Ding X. Sorafenib inhibits transforming growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2011; 53: 1708-1718.
24. Fernando J, Sancho P, Fernandez-Rodriguez CM, Lledo JL, Caja L, Campbell JS, Fausto N and Fabregat I. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 2012; 227: 1319-1325.
25. Xia H, Ooi LL and Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepat-ology 2013; 58: 629-641.
26. Avruch J, Zhang XF and Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 1994; 19: 279-283.
27. Garnett MJ, Rana S, Paterson H, Barford D and Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20: 963-969.
28. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
29. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B and Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. Jama 2010; 304: 2154-2160.
30. Finn RS, Poon RT, Yau T, Klumpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D and Bruix J. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013; 59: 1271-1277.
31. Kuendgen A and Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110: 943-954.
32. Bar EE and Stearns D. New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs 2008; 17: 185-195.
33. Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M and Gluck S. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs 2013; 22: 299-307.
34. Gotfryd K, Skladchikova G, Lepekhin EA, Berezin V, Bock E and Walmod PS. Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation. BMC Cancer 2010; 10: 383.